Literature DB >> 10764738

Microtubule-associated protein 1B is a component of cortical Lewy bodies and binds alpha-synuclein filaments.

P H Jensen1, K Islam, J Kenney, M S Nielsen, J Power, W P Gai.   

Abstract

Lewy bodies, neuropathological hallmarks of Parkinson's disease and dementia with Lewy bodies, comprise alpha-synuclein filaments and other less defined proteins. Characterization of Lewy body proteins that interact with alpha-synuclein may provide insight into the mechanism of Lewy body formation. Double immunofluorescence labeling and confocal microscopy revealed approximately 80% of cortical Lewy bodies contained microtubule-associated protein 1B (MAP-1B) that overlapped with alpha-synuclein. Lewy bodies were isolated using an immunomagnetic technique from brain tissue of patients dying with dementia with Lewy bodies. Lewy body proteins were resolved by polyacrylamide gel electrophoresis. Immunoblotting confirmed the presence of MAP-1B and alpha-synuclein in purified Lewy bodies. Direct binding studies revealed a high affinity interaction (IC(50) approximately 20 nm) between MAP-1B and alpha-synuclein. The MAP-1B-binding sites were mapped to the last 45 amino acids of the alpha-synuclein C terminus. MAP-1B also bound in vitro assembled alpha-synuclein fibrils. Thus, MAP-1B may be involved in the pathogenesis of Lewy bodies via its interaction with monomeric and fibrillar alpha-synuclein.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10764738     DOI: 10.1074/jbc.M000099200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

Review 1.  The Lewy body in Parkinson's disease and related neurodegenerative disorders.

Authors:  Koichi Wakabayashi; Kunikazu Tanji; Saori Odagiri; Yasuo Miki; Fumiaki Mori; Hitoshi Takahashi
Journal:  Mol Neurobiol       Date:  2012-05-24       Impact factor: 5.590

2.  Mitochondrial ubiquitin ligase MITOL blocks S-nitrosylated MAP1B-light chain 1-mediated mitochondrial dysfunction and neuronal cell death.

Authors:  Ryo Yonashiro; Yuya Kimijima; Takuya Shimura; Kohei Kawaguchi; Toshifumi Fukuda; Ryoko Inatome; Shigeru Yanagi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

3.  Alpha-synuclein transmission and mitochondrial toxicity in primary human foetal enteric neurons in vitro.

Authors:  Nady Braidy; Wei-Ping Gai; Ying Hua Xu; Perminder Sachdev; Gilles J Guillemin; Xing-Mai Jiang; J William O Ballard; Martin P Horan; Zhi Ming Fang; Beng H Chong; Daniel Kam Yin Chan
Journal:  Neurotox Res       Date:  2013-09-12       Impact factor: 3.911

4.  Axonal pathology in hPSC-based models of Parkinson's disease results from loss of Nrf2 transcriptional activity at the Map1b gene locus.

Authors:  Christopher Czaniecki; Tammy Ryan; Morgan G Stykel; Jennifer Drolet; Juliane Heide; Ryan Hallam; Shalandra Wood; Carla Coackley; Keith Sherriff; Craig D C Bailey; Scott D Ryan
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-24       Impact factor: 11.205

5.  Allostery in a disordered protein: oxidative modifications to α-synuclein act distally to regulate membrane binding.

Authors:  Eva Sevcsik; Adam J Trexler; Joanna M Dunn; Elizabeth Rhoades
Journal:  J Am Chem Soc       Date:  2011-04-14       Impact factor: 15.419

Review 6.  Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease.

Authors:  Heather E Allen Reish; David G Standaert
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568

7.  Phosphorylated α-synuclein in Parkinson's disease.

Authors:  Yu Wang; Min Shi; Kathryn A Chung; Cyrus P Zabetian; James B Leverenz; Daniela Berg; Karin Srulijes; John Q Trojanowski; Virginia M-Y Lee; Andrew D Siderowf; Howard Hurtig; Irene Litvan; Mya C Schiess; Elaine R Peskind; Masami Masuda; Masato Hasegawa; Xiangmin Lin; Catherine Pan; Douglas Galasko; David S Goldstein; Poul Henning Jensen; Hui Yang; Kevin C Cain; Jing Zhang
Journal:  Sci Transl Med       Date:  2012-02-15       Impact factor: 17.956

8.  Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies.

Authors:  Michael G Schlossmacher; Matthew P Frosch; Wei Ping Gai; Miguel Medina; Nutan Sharma; Lysia Forno; Tomoyo Ochiishi; Hideki Shimura; Ronit Sharon; Nobutaka Hattori; J William Langston; Yoshikuni Mizuno; Bradley T Hyman; Dennis J Selkoe; Kenneth S Kosik
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

Review 9.  Alpha-synuclein and dopamine metabolism.

Authors:  Shun Yu; Kenji Uéda; Piu Chan
Journal:  Mol Neurobiol       Date:  2005       Impact factor: 5.590

10.  Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing Parkin.

Authors:  Helen C Ardley; Gina B Scott; Stephen A Rose; Nancy G S Tan; Alexander F Markham; Philip A Robinson
Journal:  Mol Biol Cell       Date:  2003-08-22       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.